55 results on '"Sugiyama, Haruo"'
Search Results
2. Editorial overview
- Author
-
Sugiyama, Haruo
- Published
- 2008
- Full Text
- View/download PDF
3. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
- Author
-
Kosumi, Takuya, Kobayashi, Masanori, Shimodaira, Shigetaka, Sugiyama, Haruo, and Koido, Shigeo
- Subjects
- *
DENDRITIC cells , *MUCINOUS adenocarcinoma , *ANAPLASTIC lymphoma kinase , *EPIDERMAL growth factor receptors , *NEPHROBLASTOMA , *ERLOTINIB - Abstract
Background: Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms' tumor 1 and mucin 1 vaccine in combination with erlotinib, a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, for more than 699 days without recurrence or metastasis. Case presentation: A 63-year-old Korean woman was diagnosed with lung adenocarcinoma by pathology and computed tomography. The adenocarcinoma showed an epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase expression, and less than 1% expression of programmed death ligand 1. She received erlotinib alone for approximately 1 month. She then received erlotinib and the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine. The diameter of the erythema at the vaccinated sites was 30 mm at 48 hours after the first vaccination. Moreover, it was maintained at more than 20 mm during the periods of vaccination. These results suggested the induction of antitumor immunity by the vaccine. Remarkably, the tumor size decreased significantly to 12 mm, a 65.7% reduction, after combined therapy with eight doses of the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine and erlotinib for 237 days based on fluorodeoxyglucose uptake by positron emission tomography/computed tomography and computed tomography. Interestingly, after 321 days of combination therapy, the clinical findings improved, and no tumor was detected based on computed tomography. Validation of the tumor's disappearance persisted for at least 587 days after treatment initiation, without any indication of recurrence or metastasis. Conclusion: Standard anticancer therapy combined with the dendritic cells pulsed with Wilms' tumor 1 and mucin 1 vaccine may have therapeutic effects for such patients with unresectable lung adenocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Bayesian predictive model averaging approach to joint longitudinal‐survival modeling: Application to an immuno‐oncology clinical trial.
- Author
-
Yao, Zixuan, Morita, Satoshi, Nishida, Sumiyuki, and Sugiyama, Haruo
- Subjects
- *
PREDICTION models , *CLINICAL trials , *CLINICAL medicine , *CANCER patients - Abstract
Summary: In immuno‐oncology clinical trials, multiple immunological biomarkers are usually examined over time to comprehensively and appropriately evaluate the efficacy of treatments. Because predicting patients' future survival statuses on the basis of such recorded longitudinal information might be of great interest, joint modeling of longitudinal and time‐to‐event data has been intensively discussed as a toolkit to implement such a prediction. To achieve a desirable predictive performance, averaging over multiple candidate predictive models to account for the model uncertainty might be a more suitable statistical approach than selecting the single best model. Although Bayesian model averaging can be one of the approaches, several problems related to model weights with marginal likelihoods have been discussed. To address these problems, we here propose a Bayesian predictive model averaging (BPMA) method that uses Bayesian leave‐one‐out cross‐validation predictive densities to account for the subject‐specific and time‐dependent nature of the prediction. We examine the operating characteristics of the proposed BPMA method in terms of the predictive accuracy (ie, the calibration and discrimination abilities) in extensive simulation studies. In addition, we discuss the strengths and limitations of the proposed method by applying it to an immuno‐oncology clinical trial in patients with advanced ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
- Author
-
Fujiki, Fumihiro, Morimoto, Soyoko, Nishida, Yuya, Tanii, Satoe, Aoyama, Nao, Inatome, Miki, Inoue, Kento, Katsuhara, Akiko, Nakajima, Hiroko, Nakata, Jun, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Oji, Yusuke, Sogo, Shinji, and Sugiyama, Haruo
- Subjects
- *
T cells , *PEPTIDES , *CELL lines , *AMINO acids , *CLINICAL medicine - Abstract
CD4+ T cells that recognize antigenic peptides presented on HLA class II are essential for inducing an optimal anti-tumor immune response, and adoptive transfer of tumor antigen-specific TCR-transduced CD4+ T cells with high responsiveness against tumor is a promising strategy for cancer treatment. Whereas a precise evaluation method of functional avidity, an indicator of T cell responsiveness against tumors, has been established for HLA class I-restricted TCRs, it remains unestablished for HLA class II-restricted TCRs. In this study, we generated a novel platform cell line, CD4-2D3, in which GFP reporter was expressed by NFAT activation via TCR signaling, for correctly evaluating functional avidity of HLA class II-restricted TCRs. Furthermore, using this platform cell line, we succeeded in maturating functional avidity of an HLA class II-restricted TCR specific for a WT1-derived helper peptide by substituting amino acids in complementarity determining region 3 (CDR3) of the TCR. Importantly, we demonstrated that transduction of an avidity-maturated TCR conferred strong cytotoxicity against WT1-expressing leukemia cells on CD4+ T cells, compared to that of its original TCR. Thus, CD4-2D3 cell line should be useful not only to evaluate TCR functional avidity in HLA class II-restricted TCRs but also to screen appropriate TCRs for clinical applications such as cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The Detection of Immunity against WT1 and SMAD4 P130L of EpCAM + Cancer Cells in Malignant Pleural Effusion.
- Author
-
Koya, Terutsugu, Niida, Yo, Togi, Misa, Yoshida, Kenichi, Sakamoto, Takuya, Ura, Hiroki, Togi, Sumihito, Kato Jr., Tomohisa, Yamada, Sohsuke, Sugiyama, Haruo, Koido, Shigeo, and Shimodaira, Shigetaka
- Subjects
- *
CANCER cells , *PLEURAL effusions , *CELL adhesion molecules , *PROGRAMMED cell death 1 receptors , *NEPHROBLASTOMA , *CYTOTOXIC T cells , *T cells , *EPITHELIAL cells - Abstract
Malignant pleural effusion (MPE) provides a liquid tumor microenvironment model that includes cancer cells and immune cells. However, the characteristics of tumor antigen-specific CD8+ T cells have not been investigated in detail. Here, we analyzed MPE samples taken from a patient with pancreatic cancer who received a dendritic cell vaccine targeting Wilms' Tumor 1 (WT1) antigen over the disease course (two points at MPE1st and 2nd, two months after MPE1st). Epithelial cell adhesion molecule (EpCAM)+ cancer cells (PD-L1− or T cell immunoglobulin mucin-3, TIM-3−), both PD-1 or TIM-3 positive CD8+ T cells, and CD14+CD68+CD163+TIM-3+ macrophages increased from the MPE1st to MPE2nd. The ratio of WT1-specific cytotoxic lymphocytes (WT1-CTLs) to MPE CD8+ T cells and IFN-γ secretion of WT1-CTLs were reduced with disease progression. Coincidentally, the fraction of central memory T (TCM) of WT1-CTLs was decreased. On the other hand, CD8+ T cells in response to SMAD4P130L, which is homogeneously expressed in EpCAM+ cancer cells, were detected using in vitro expansion with the HLA-A*11:01 restrictive SVCVNLYH neoantigen. Furthermore, the CD8+ T cell response to SMAD4P130L was diminished following remarkably decreased numbers of CD8+ TCM in MPE samples. In conclusion, CD8+ T cells responding to WT1 or SMAD4P130L neoantigen expressed in EpCAM+ pancreatic cancer cells were detected in MPE. A tumor antigen-specific immune response would provide novel insight into the MPE microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
- Author
-
Yokota, Chisato, Kagawa, Naoki, Takano, Koji, Chiba, Yasuyoshi, Kinoshita, Manabu, Kijima, Noriyuki, Oji, Yusuke, Oka, Yoshihiro, Sugiyama, Haruo, Tsuboi, Akihiro, Izumoto, Shuichi, Kishima, Haruhiko, and Hashimoto, Naoya
- Subjects
- *
GLIOMAS , *PEPTIDES , *BRAIN tumors , *NEPHROBLASTOMA , *PROGNOSIS , *TUMOR antigens , *HLA-B27 antigen , *HISTOCOMPATIBILITY class I antigens - Abstract
We have previously revealed the overexpression of Wilms' tumor gene 1 (WT1) in malignant glioma and developed WT1 peptide vaccine cancer immunotherapy. A phase II clinical trial indicated the clinical efficacy of the WT1 peptide vaccine for recurrent malignant glioma. Here, we aimed to investigate the immunological microenvironment in glioma tissues before and after WT1 peptide vaccine treatment. Paired tissue samples were obtained from 20 malignant glioma patients who had received the WT1 peptide vaccine for > 3 months and experienced tumor progression, confirmed radiographically and/or clinically, during vaccination. We discovered that the expression of WT1 and HLA class I antigens in the tumor cells significantly decreased after vaccination. Maintenance of WT1 expression, which is the target molecule of immunotherapy, in tumor cells during the vaccination period was significantly associated with a longer progression-free and overall survival. A high expression of HLA class I antigens and low CD4+/CD8+ tumor-infiltrating lymphocytes (TIL) ratio in pre-vaccination specimens, were also associated with a good prognosis. No statistically significant difference existed in the number of infiltrating CD3+ or CD8+ T cells between the pre- and post-vaccination specimens, whereas the number of infiltrating CD4+ T cells significantly decreased in the post-vaccination specimens. This study provides insight into the mechanisms of intra-tumoral immune reaction/escape during WT1 peptide vaccine treatment and suggests potential clinical strategies for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
- Author
-
Kiryu, Sachie, Ito, Zensho, Suka, Machi, Bito, Tsuuse, Kan, Shin, Uchiyama, Kan, Saruta, Masayuki, Hata, Taigo, Takano, Yuki, Fujioka, Shuichi, Misawa, Takeyuki, Yamauchi, Takashi, Yanagisawa, Hiroyuki, Sato, Nobuhiro, Ohkusa, Toshifumi, Sugiyama, Haruo, and Koido, Shigeo
- Subjects
- *
REGULATORY T cells , *PROGNOSIS , *TUMOR microenvironment , *OVERALL survival , *T cells , *PANCREATIC surgery , *LYMPHOCYTE metabolism , *PROTEIN metabolism , *PANCREATIC tumors , *PANCREAS , *CANCER relapse , *CELL physiology , *RETROSPECTIVE studies , *LYMPHOCYTES , *DUCTAL carcinoma , *PANCREATECTOMY , *ANTIGENS , *LONGITUDINAL method - Abstract
Background: Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cells, such as regulatory T cells (Tregs), in the tumor microenvironment (TME) play an important role in the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC).Methods: The densities of TILs, programmed death receptor 1 (PD-1) + T cells, and forkhead box P3 (Foxp3) + T cells were analyzed by immunohistochemical staining. The associations of the immunological status of the PDAC microenvironment with overall survival (OS) time and disease-free survival (DFS) time were evaluated.Results: PDAC patients with a high density of TILs in the TME or PD-1-positive T cells in tertiary lymphoid aggregates (TLAs) demonstrated a significantly better prognosis than those with a low density of TILs or PD-1-negativity, respectively. Moreover, PDAC patients with high levels of Foxp3-expressing T cells showed a worse prognosis than those with low levels of Foxp3-expressing T cells. Importantly, even with a high density of the TILs in TME or PD-1-positive T cells in TLAs, PDAC patients with high levels of Foxp3-expressing T cells showed a worse prognosis than patients with low levels of Foxp3-expressing T cells. A PDAC TME with a high density of TILs/high PD-1 positivity/low Foxp3 expression was an independent predictive marker associated with superior prognosis.Conclusion: Combined assessment of TILs, PD-1+ cells, and Foxp3+ T cells in the TME may predict the prognosis of PDAC patients following surgical resection. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
- Author
-
Nakajima, Hiroko, Nakata, Jun, Imafuku, Kanako, Hayashibara, Hiromu, Isokawa, Kazuki, Udaka, Keiko, Fujiki, Fumihiro, Morimoto, Soyoko, Hasegawa, Kana, Hosen, Naoki, Hashii, Yoshiko, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Oji, Yusuke, Sogo, Shinji, and Sugiyama, Haruo
- Subjects
- *
T cells , *CYTOTOXIC T cells , *LABORATORY mice , *EPITOPES , *MICE , *REJECTION (Psychology) - Abstract
Helper T lymphocytes (HTLs) play a central role in cancer immunity because they can not only help the induction and proliferation of cytotoxic T lymphocytes (CTLs) but also their differentiation into cytotoxic CD4+ T cells and directly kill the target cells.This study describes the identification of three novel mouse Th epitope peptides, WT135-52, WT186-102 and WT1294-312, derived from WT1 protein, which is the most potent tumor-associated antigen. Compared to immunization with WT1 CTL peptide alone, immunization with the addition of these WT1-specific Th peptides strongly induced WT1-specific CTLs, continued to maintain them, and efficiently rejected the challenge of WT1-expressing tumor cells. Importantly, the majority of WT1-specific CTLs induced by the co-immunization with WT1 CTL and the WT1-specific Th peptides were CD44+CD62L− effector memory CD8+ T cells, which played a central role in tumor rejection. Establishment of mouse models suitable for the analysis of the detailed mechanism of these functions of HTLs is very important. These results clearly showed that WT1-specific HTLs perform an essential function in WT1-specific tumor immunity. Therefore, the WT1-specific Th peptides identified here should make a major contribution to elucidation of the mutual roles of WT1-specific CTLs and HTLs in cancer immunity in in vivo mouse models. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Transient Hyper-17-OHPnemia Unrelated to Cross-Reactions with Residual Fetal Adrenal Cortex Products.
- Author
-
Mizuno, Haruo, Yoichiro Ohro, Haruo, Yukari Sugiyama, Haruo, Tetsuya Ito, Haruo, Hasegawa, Tomonobu, Keiko Homma, Tomonobu, Hajime Ueshiba, Tomonobu, Ono, Makoto, and Hajime Togari
- Subjects
- *
HYDROXYPROGESTERONE , *LIQUID chromatography , *RADIOIMMUNOASSAY , *MASS spectrometry , *GAS chromatography - Abstract
Objective: To clarify the pathogenesis of transient hyper-17α-hydroxyprogesteronemia, we initiated a laboratory investigation in a pre-term infant with persistently high serum 17α-hydroxyprogesterone (17-OHP) until 2 months of age. Methods: Serum 17-OHP level was measured by high-performance liquid chromatography and radioimmunoassay, and gene analysis of CYP21A2 (21-hydroxylase) was performed. Result: Serum 17-OHP level on the 29th day of life was 25.4 ng/ml, and the urinary steroid profile showed low pregnanetriolone. Gene analysis of 21-hydroxylase disclosed no mutation, and 17-OHP normalized by 3 months of age without specific treatment. Conclusion: Transient elevations in 17-OHP, which do not appear related to cross-reactions with products of a residual fetal adrenal cortex, may occur in the first few months of life. Copyright © 2004 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
11. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
- Author
-
Fujiki, Fumihiro, Tsuboi, Akihiro, Morimoto, Soyoko, Hashimoto, Naoya, Inatome, Miki, Nakajima, Hiroko, Nakata, Jun, Nishida, Sumiyuki, Hasegawa, Kana, Hosen, Naoki, Oka, Yoshihiro, Oji, Yusuke, Sogo, Shinji, and Sugiyama, Haruo
- Subjects
- *
CYTOTOXIC T cells , *T cells , *PEPTIDES , *BCG vaccines , *CELL death - Abstract
Simultaneous induction of tumor antigen-specific cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) is required for an optimal anti-tumor immune response. WT1332, a 16-mer WT1-derived helper peptide, induce HTLs in an HLA class II-restricted manner and enhance the induction of WT1-specific CTLs in vitro. However, in vivo immune reaction to WT1332 vaccination in tumor-bearing patients remained unclear. Here, a striking difference in WT1-specific T cell responses was shown between WT1 CTL + WT1 helper peptide and WT1 CTL peptide vaccines in patients with recurrent glioma. WT1-specific CTLs were more strongly induced in the patients who were immunized with WT1 CTL + WT1 helper peptide vaccine, compared to those who were immunized with WT1 CTL vaccine alone. Importantly, a clear correlation was demonstrated between WT1-specific CTL and WT1332-specific HTL responses. Interestingly, two novel distinct populations of WT1-tetramerlow WT1-TCRlow CD5low and WT1-tetramerhigh WT1-TCRhigh CD5high CTLs were dominantly detected in WT1 CTL + WT1 helper peptide vaccine. Although natural WT1 peptide-reactive CTLs in the latter population were evidently less than those in the former population, the latter population showed natural WT1 peptide-specific proliferation capacity comparable to the former population, suggesting that the latter population highly expressing CD5, a marker of resistance to activation-induced cell death, should strongly expand and persist for a long time in patients. These results demonstrated the advantage of WT1 helper peptide vaccine for the enhancement of WT1-specific CTL induction by WT1 CTL peptide vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy.
- Author
-
Hayashi, Sae, Imanishi, Rin, Adachi, Mayuko, Ikejima, Sayaka, Nakata, Jun, Morimoto, Soyoko, Fujiki, Fumihiro, Nishida, Sumiyuki, Tsuboi, Akihiro, Hosen, Naoki, Nakajima, Hiroko, Hasegawa, Kana, Oka, Yoshihiro, Sugiyama, Haruo, and Oji, Yusuke
- Subjects
- *
CANCER vaccines , *NEPHROBLASTOMA , *IMMUNOTHERAPY , *IMMUNE response , *BACTERIAL vaccines , *PARTICLE analysis - Abstract
Cancer vaccine immunotherapy is a therapy that induces cellular immune responses against a target molecule to elicit clinical anti-tumor effects. These cellular immune responses against the target molecule are monitored to evaluate whether the antigen-specific cellular immune responses are induced and maintained during the vaccination period. Enzyme-linked immunospot (ELISPOT) assay is widely performed to analyze not only the frequency of immune cells, but also their effector functions as determined by their cytokine production/secretion. The present study aimed to develop a reader-free ELISPOT assay using a handy membrane-punching device termed ELI 8. With the assistance of particle analysis by ImageJ software, the results of spot counting were reproducible with high inter-assay and inter-examiner concordance. Immune cells that produce and secrete Th1 cytokines without antigen-peptide stimulation of peripheral blood mononuclear cells (PBMCs) were detected, and their frequencies in patients with cancer were significantly higher compared with those in healthy individuals. These frequencies varied between individuals, as well as between time points during the course of cancer vaccine immunotherapy in each patient. Due to the variability in spontaneous cytokine production/secretion by PBMCs, an antigen-specific immune response (IR) index is proposed, which is a ratio of the number of spot-forming cells (SFCs) subjected to antigen-stimulation to that of SFCs with spontaneous cytokine secretion without antigen-stimulation. This index may be used as a marker for antigen-specific cellular immune responses in patients treated with cancer immunotherapy. The IR index successfully detected the induction of Wilms' tumor 1-specific cellular immune responses in patients with cancer treated with cancer vaccine immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer.
- Author
-
Yoshida, Sayumi, Ito, Zensho, Suka, Machi, Bito, Tsuuse, Kan, Shin, Akasu, Takafumi, Saruta, Masayuki, Okamoto, Masato, Kitamura, Hiroaki, Fujioka, Shuichi, Misawa, Takeyuki, Akiba, Tadashi, Yanagisawa, Hiroyuki, Sugiyama, Haruo, and Koido, Shigeo
- Subjects
- *
ADENOCARCINOMA , *APOPTOSIS , *CANCER patients , *GENE expression , *LIGANDS (Biochemistry) , *PANCREATIC tumors , *T cells - Abstract
The associations of the immunological status of the pancreatic ductal adenocarcinoma (PDA) microenvironment with prognosis were assessed. A high tumor-infiltrating lymphocyte (TIL) density was associated with a better prognosis. Importantly, even with a high density of TILs, the PDA cells with programed cell death-ligand 1 (PD-L1) expression showed a worse prognosis than the patients with negative PD-L1 expression. A significant association between a better prognosis and a tumor microenvironment with a high TIL density/negative PD-L1 expression was observed. Assessments of a combined immunological status in the tumor microenvironment may predict the prognosis of PDA patients following surgical resection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
- Author
-
Ito, Zensho, Kan, Shin, Bito, Tsuuse, Horiuchi, Sankichi, Akasu, Takafumi, Yoshida, Sayumi, Kajihara, Mikio, Hokari, Atsushi, Saruta, Masayuki, Yoshida, Noriyuki, Kobayashi, Masanori, Ohkusa, Toshifumi, Shimodaira, Shigetaka, Okamoto, Masato, Sugiyama, Haruo, and Koido, Shigeo
- Subjects
- *
THERAPEUTIC use of antimetabolites , *ADENOCARCINOMA , *BIOMARKERS , *CANCER chemotherapy , *CANCER patients , *CLINICAL trials , *DENDRITIC cells , *GRANULOCYTES , *NEPHROBLASTOMA , *PANCREATIC tumors , *SURVIVAL , *TUMOR markers , *CANCER vaccines , *MATRIX metalloproteinases - Abstract
Background: We have developed a Wilms' tumor 1 (WT1)-targeting dendritic cell (DC)-based cancer vaccine combined with standard chemotherapy for patients with advanced pancreatic ductal adenocarcinoma (PDA). Methods: We evaluated predictive markers of overall survival (OS) in PDA patients treated with multiple major histocompatibility complex class I/II-restricted, WT1 peptide-pulsed DC vaccinations (DC/WT1-I/II) in combination with chemotherapy. Throughout the entire period of immunochemotherapy, the plasma levels of soluble factors derived from granulocytes of 7 eligible PDA patients were examined. Moreover, systemic inflammatory response markers (neutrophil-to-lymphocyte ratio [NLR], monocyte-to-lymphocyte ratio [MLR], and granulocyte-to-lymphocyte ratio [GLR]) were assessed. In addition, cytoplasmic WT1 expression in PDA cells was examined. Results: Compared to the 4 non-super-responders (OS <1 year), the remaining 3 super-responders (OS ≥1 year) showed significantly decreased low plasma matrix metalloproteinase-9 levels throughout long-term therapy. The NLR, MLR, and GLR after 5 DC/WT1-I/II vaccinations and 3 cycles of gemcitabine were significantly lower in the super-responders than in the non-super-responders. Furthermore, the cytoplasmic WT1 expression in the PDA cells of super-responders was relatively weak compared to that in the PDA cells of non-super-responders. Conclusions: Prolonged low levels of a granulocyte-related systemic inflammatory response after the early period of therapy and low cytoplasmic WT1 expression in PDA cells may be markers predictive of OS in PDA patients receiving WT1-targeting immunochemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
- Author
-
Tsuboi, Akihiro, Hashimoto, Naoya, Fujiki, Fumihiro, Morimoto, Soyoko, Kagawa, Naoki, Nakajima, Hiroko, Hosen, Naoki, Nishida, Sumiyuki, Nakata, Jun, Morita, Satoshi, Sakamoto, Junichi, Oji, Yusuke, Oka, Yoshihiro, and Sugiyama, Haruo
- Subjects
- *
NEPHROBLASTOMA , *GLIOMAS , *ANTIGENS , *HLA histocompatibility antigens , *CANCER relapse , *CANCER vaccines , *PEPTIDES , *CANCER treatment - Abstract
Purpose: The safety and clinical efficacy of WT1 human leukocyte antigen (HLA) class I peptide vaccine have been established, but the safety of a cocktail vaccine of WT1 HLA class I and II peptides has not. To verify its safety, we performed a phase I clinical trial for patients with recurrent malignant gliomas and assessed the immunological responses and survival data.Patients and methods: Fourteen HLA-A*24:02-positive patients with recurrent malignant glioma (2 with grade 3, 12 with grade 4) were enrolled. Every week, the patients received alternately a vaccine containing 3 mg of WT1 HLA-A*24:02-restricted (HLA class I) peptide and a cocktail vaccine of the HLA class I peptide and one of 0.75, 1.5 or 3 mg of the WT1 HLA class II peptide. For patients who showed no significant adverse effects within 6 weeks, the WT1 vaccine was continued at 2-4-week intervals.Results: Eleven of the 14 patients completed WT1 vaccination for 6 weeks, while 3 patients dropped out earlier due to disease progression. All patients showed grade I level of skin disorders at the injection sites. No grade III/IV toxicity or dose-limiting toxicity was observed for any dose of WT1 HLA class II peptide. Six of the 14 patients had stable disease at 6 weeks. Median OS and 1-year OS rates were 24.7 weeks and 36%, respectively.Conclusion: The safety of a cocktail vaccine of WT1 HLA class I and II peptides for malignant gliomas was verified. This vaccine is, therefore, considered promising for patients with recurrent malignant glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.
- Author
-
Kanai, Tomoya, Ito, ZENsho, Oji, Yusuke, Suka, Machi, Nishida, Sumiyuki, Takakura, Kazuki, Kajihara, Mikio, Saruta, Masayuki, Fujioka, Shuichi, Misawa, Takeyuki, Akiba, Tadashi, Yanagisawa, Hiroyuki, Shimodaira, Shigetaka, Okamoto, Masato, Sugiyama, Haruo, and Koido, Shigeo
- Subjects
- *
PANCREATIC cancer , *ADENOCARCINOMA , *CANCER chemotherapy , *METASTASIS , *PROGRESSION-free survival - Abstract
The only current curative treatment for patients with pancreatic ductal adenocarcinoma (PDA) is surgical resection, and certain patients still succumb to disease shortly after complete surgical resection. Wilms' tumor 1 (WT1) serves an oncogenic role in various types of tumors; therefore, in the present study, WT1 protein expression in patients with PDA was analyzed and the association with overall survival (OS) and disease-free survival (DFS) time in patients with PDA was assessed following surgical resection. A total of 50 consecutive patients with PDA who received surgical resection between January 2005 and December 2015 at the Jikei University Kashiwa Hospital (Kashiwa, Chiba, Japan) were enrolled. WT1 protein expression in PDA tissue was measured using immunohistochemical staining. Furthermore, laboratory parameters were measured within 2 weeks of surgery, and systemic inflammatory response markers were evaluated. WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells and in tumor vessels. WT1 exhibited weak staining in the nuclei of all PDA cells; however, the cytoplasmic expression of WT1 levels was classified into four groups: Negative (n=0), weak (n=19), moderate (n=23) and strong (n=8). In patients with PDA, it was demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression, as determined by log-rank test (P=0.0005 and P=0.0001, respectively). Furthermore, an association between the density of WT1-expressing tumor vessels and worse OS/DFS times was detected. Multivariate analysis also indicated a significant association between the overexpression of WT1 in PDA tissue and worse OS/DFS times. To the best of our knowledge, the present study is the first to demonstrate that moderate-to-strong overexpression of WT1 in the cytoplasm of PDA cells is significantly associated with worse OS/DFS times. Therefore, overexpression of WT1 in the cytoplasm of PDA cells may impact the recurrence and prognosis of patients with PDA following surgical resection. The results further support the development of WT1-targeted therapies to prolong survival in all patients with PDA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.
- Author
-
Nakata, Jun, Nakae, Yoshiki, Kawakami, Manabu, Morimoto, Soyoko, Motooka, Daisuke, Hosen, Naoki, Fujiki, Fumihiro, Nakajima, Hiroko, Hasegawa, Kana, Nishida, Sumiyuki, Tsuboi, Akihiro, Oji, Yusuke, Oka, Yoshihiro, Kumanogoh, Atsushi, and Sugiyama, Haruo
- Subjects
- *
VACCINES , *TUMORS , *ACUTE myeloid leukemia , *DRUG therapy , *BIOLOGICALS - Abstract
The article presents the clinical results as well as immunological findings of a phase 2 clinical study of Wilms tumour 1 peptide vaccine. It focuses on acute myeloid leukaemia patients who achieved haematological complete remission following chemotherapy but were susceptible to relapse. The peptide vaccination was repeated after every two weeks in the first six months.
- Published
- 2018
- Full Text
- View/download PDF
18. Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8+ T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells.
- Author
-
Coelho-dos-Reis, Jordana G., Huang, Jing, Tsao, Tiffany, Pereira, Felipe V., Funakoshi, Ryota, Nakajima, Hiroko, Sugiyama, Haruo, and Tsuji, Moriya
- Subjects
- *
NEPHROBLASTOMA , *IMMUNE response , *IMMUNOLOGICAL adjuvants , *T cells , *TOLL-like receptors , *VASCULAR cell adhesion molecule-1 , *KILLER cells , *PREVENTION , *PHYSIOLOGY - Abstract
In the present study, the combined adjuvant effect of 7DW8-5, a potent α-GalCer-analog, and monophosphoryl lipid A (MPLA), a TLR4 agonist, on the induction of vaccine-induced CD8 + T-cell responses and protective immunity was evaluated. Mice were immunized with peptides corresponding to the CD8 + T-cell epitopes of a malaria antigen, a circumsporozoite protein of Plasmodium yoelii , and a tumor antigen, a Wilms Tumor antigen-1 (WT-1), together with 7DW8-5 and MPLA, as an adjuvant. These immunization regimens were able to induce higher levels of CD8 + T-cell responses and, ultimately, enhanced levels of protection against malaria and tumor challenges compared to the levels induced by immunization with peptides mixed with 7DW8-5 or MPLA alone. Co-administration of 7DW8-5 and MPLA induces activation of memory-like effector natural killer T (NKT) cells, i.e. CD44 + CD62L − NKT cells. Our study indicates that 7DW8-5 greatly enhances important synergistic pathways associated to memory immune responses when co-administered with MPLA, thus rendering this combination of adjuvants a novel vaccine adjuvant formulation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.
- Author
-
Hasegawa, Kana, Tanaka, Satomi, Fujiki, Fumihiro, Morimoto, Soyoko, Nakajima, Hiroko, Tatsumi, Naoya, Nakata, Jun, Takashima, Satoshi, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Oji, Yusuke, Kumanogoh, Atsushi, Sugiyama, Haruo, and Hosen, Naoki
- Subjects
- *
LEUKEMIA , *IMMUNE response , *CYTOTOXIC T cells , *ANTIGENS , *GENE expression , *LABORATORY mice - Abstract
Leukemia differs substantially with respect to stromal milieu from tumors that progress locally as solid masses, and the physiological importance of immunosurveillance in leukemia remains unclear. However, currently available mouse leukemia models have critical limitations in the context of analyzing immunological regulation of leukemia development. In this study, we transferred mouse MLL/AF9 leukemia-initiating cells into immunocompetent recipient mice without any pre-conditioning such as irradiation, and then analyzed the spontaneous T cell response to an immunogenic antigen expressed in leukemia cells. When the minimum numbers of leukemia-initiating cells for engraftment were transferred, leukemia cells were eradicated by the adaptive immune response in most, if not all, wild-type mice, but not in Rag2-/- recipient mice, which lack adaptive immunity. By contrast, mice transplanted with larger numbers of leukemia cells always developed leukemia. In mice with advanced leukemia, antigen-specific CTLs were also expanded, but were unresponsive to antigen stimulation and expressed high levels of PD-1 and LAG-3. These results provide the first clear demonstration that the spontaneous CTL response to a tumor-cell antigen has the potential to eradicate leukemia, whereas antigen-specific CTLs are exhausted in animals with advanced leukemia. This immunocompetent mouse leukemia model provides a useful platform for developing effective immunotherapies against leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
- Author
-
Nakae, Yoshiki, Oka, Yoshihiro, Fujiki, Fumihiro, Morimoto, Soyoko, Kamiya, Toshio, Takashima, Satoshi, Nakata, Jun, Nishida, Sumiyuki, Nakajima, Hiroko, Hosen, Naoki, Tsuboi, Akihiro, Kyo, Taiichi, Oji, Yusuke, Mizuguchi, Kenji, Kumanogoh, Atsushi, and Sugiyama, Haruo
- Subjects
- *
ACUTE myeloid leukemia treatment , *NEPHROBLASTOMA , *CYTOTOXIC T cells , *LYMPHOCYTES , *GENE expression , *THERAPEUTICS - Abstract
Wilms' tumor gene 1 (WT1) protein is a promising tumor-associated antigen for cancer immunotherapy. We have been performing WT1 peptide vaccination with good clinical responses in over 750 patients with leukemia or solid cancers. In this study, we generated single-cell gene-expression profiles of the effector memory (EM) subset of WT1-specific cytotoxic T lymphocytes (CTLs) in peripheral blood of nine acute myeloid leukemia patients treated with WT1 peptide vaccine, in order to discriminate responders ( WT1 mRNA levels in peripheral blood decreased to undetectable levels, decreased but stayed at abnormal levels, were stable at undetectable levels, or remained unchanged from the initial abnormal levels more than 6 months after WT1 vaccination) from non-responders (leukemic blast cells and/or WT1 mRNA levels increased relative to the initial state within 6 months of WT1 vaccination) prior to WT1 vaccination. Cluster and principal component analyses performed using 83 genes did not discriminate between responders and non-responders prior to WT1 vaccination. However, these analyses revealed that EM subset of WT1-specific CTLs could be divided into two groups: the 'activated' and 'quiescent' states; in responders, EM subset of the CTLs shifted to the 'quiescent' state, whereas in non-responders, those shifted to the 'activated' state following WT1 vaccination. These results demonstrate for the first time the existence of two distinct EM states, each of which was characteristic of responders or non-responders, of WT1-specific CTLs in AML patients, and raises the possibility of using advanced gene-expression profile analysis to clearly discriminate between responders and non-responders prior to WT1 vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
- Author
-
Hashimoto, Naoya, Tsuboi, Akihiro, Kagawa, Naoki, Chiba, Yasuyoshi, Izumoto, Shuichi, Kinoshita, Manabu, Kijima, Noriyuki, Oka, Yoshihiro, Morimoto, Soyoko, Nakajima, Hiroko, Morita, Satoshi, Sakamoto, Junichi, Nishida, Sumiyuki, Hosen, Naoki, Oji, Yusuke, Arita, Norio, Yoshimine, Toshiki, and Sugiyama, Haruo
- Subjects
- *
NEPHROBLASTOMA , *GLIOBLASTOMA multiforme , *VACCINATION , *TEMOZOLOMIDE , *VACCINE safety , *PATIENTS , *DIAGNOSIS , *THERAPEUTICS - Abstract
To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed. Seven patients with histological diagnosis of glioblastoma underwent concurrent radiotherapy and temozolomide therapy. Patients first received Wilms tumor 1 peptide vaccination 1 week after the end of combined concurrent radio/temozolomide therapy, and administration was continued once per week for 7 weeks. Temozolomide maintenance was started and performed for up to 24 cycles, and the observation period for safety encompassed 6 weeks from the first administration of maintenance temozolomide. All patients showed good tolerability during the observation period. Skin disorders, such as grade 1/2 injection-site reactions, were observed in all seven patients. Although grade 3 lymphocytopenia potentially due to concurrent radio/temozolomide therapy was observed in five patients (71.4 %), no other grade 3/4 hematological or neurological toxicities were observed. No autoimmune reactions were observed. All patients are still alive, and six are on Wilms tumor 1 peptide vaccination without progression, yielding a progression-free survival from histological diagnosis of 5.2-49.1 months. Wilms tumor 1 peptide vaccination was stopped in one patient after 12 injections by the patient's request. The safety profile of the combined Wilms tumor 1 peptide vaccination and temozolomide therapy approach for treating glioblastoma was confirmed. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.
- Author
-
Tatsumi, Naoya, Hojo, Nozomi, Sakamoto, Hiroyuki, Inaba, Rena, Moriguchi, Nahoko, Matsuno, Keiko, Fukuda, Mari, Matsumura, Akihide, Hayashi, Seiji, Morimoto, Soyoko, Nakata, Jun, Fujiki, Fumihiro, Nishida, Sumiyuki, Nakajima, Hiroko, Tsuboi, Akihiro, Oka, Yoshihiro, Hosen, Naoki, Sugiyama, Haruo, and Oji, Yusuke
- Subjects
- *
NEPHROBLASTOMA , *C-terminal residues , *EXONS (Genetics) , *GENETIC code , *GENETIC engineering , *CANCER cell proliferation , *GENETICS - Abstract
The Wilms’ tumor gene WT1 consists of 10 exons and encodes a zinc finger transcription factor. There are four major WT1 isoforms resulting from alternative splicing at two sites, exon 5 (17AA) and exon 9 (KTS). All major WT1 isoforms are overexpressed in leukemia and solid tumors and play oncogenic roles such as inhibition of apoptosis, and promotion of cell proliferation, migration and invasion. In the present study, a novel alternatively spliced WT1 isoform that had an extended exon 4 (designated as exon 4a) with an additional 153 bp (designated as 4a sequence) at the 3’ end was identified and designated as an Ex4a(+)WT1 isoform. The insertion of exon 4a resulted in the introduction of premature translational stop codons in the reading frame in exon 4a and production of C-terminal truncated WT1 proteins lacking zinc finger DNA-binding domain. Overexpression of the truncated Ex4a(+)WT1 isoform inhibited the major WT1-mediated transcriptional activation of anti-apoptotic Bcl-xL gene promoter and induced mitochondrial damage and apoptosis. Conversely, suppression of the Ex4a(+)WT1 isoform by Ex4a-specific siRNA attenuated apoptosis. These results indicated that the Ex4a(+)WT1 isoform exerted dominant negative effects on anti-apoptotic function of major WT1 isoforms. Ex4a(+)WT1 isoform was endogenously expressed as a minor isoform in myeloid leukemia and solid tumor cells and increased regardless of decrease in major WT1 isoforms during apoptosis, suggesting the dominant negative effects on anti-apoptotic function of major WT1 isoforms. These results indicated that Ex4a(+)WT1 isoform had an important physiological function that regulated oncogenic function of major WT1 isoforms. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc.
- Author
-
Wu, Chen, Wang, Sihan, Xu, Caihua, Tyler, andreas, Li, Xingru, andersson, Charlotta, Oji, Yusuke, Sugiyama, Haruo, Chen, Yijiang, and Li, aihong
- Subjects
- *
CELL proliferation , *APOPTOSIS , *GENETIC mutation , *CELLULAR signal transduction , *GENE expression , *SMALL interfering RNA , *PLASMIDS - Abstract
Background: A novel link between oncogenic KRAS signalling and WT1 was recently identified. We sought to investigate the role of WT1 and KRAS in proliferation and apoptosis. Methods: KRAS mutations and WT1 (cMyc) expression were detected using Sanger sequencing and real-time PCR in 77 patients with non-small cell lung cancer (NSCLC). Overexpression and knockdown of WT1 were generated with plasmid and siRNA via transient transfection technology in H1299 and H1568 cells. MTT assay for detection of cell proliferation, and TUNEL assay and proteomic profiler assay for apoptosis evaluation were carried out. Dual luciferase reporter assay and ChIP-PCR were performed to validate the effect of WT1 on the cMyc promoter. Results: KRAS mutations showed a negative impact on overall survival (OS). High expressions of WT1 and cMyc were associated with poor OS in KRAS mutant subgroup. The potential mechanisms that WT1 promotes proliferation and impedes apoptosis through affecting multiple apoptosis-related regulators in KRAS mutant NSCLC cells were identified. WT1 could activate cMyc promoter directly in KRAS mutant cells. Conclusion: The results suggest that WT1 and c-MYC expression is important for survival in KRAS mutant tumors as opposed to KRAS wild-type tumors. For treatment of KRAS mutant NSCLC, targeting WT1 and cMyc may provide alternative therapeutic strategies. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Prognostic significance of specific anti- WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
- Author
-
Andersson, Charlotta, Oji, Yusuke, Ohlson, Nina, Wang, Sihan, Li, Xingru, Ottander, Ulrika, Lundin, Eva, Sugiyama, Haruo, and Li, Aihong
- Subjects
- *
CARCINOMA , *OVARIAN cancer , *CANCER , *IMMUNOGLOBULIN G , *TUMORS - Abstract
Ovarian carcinoma ( OC) has a poor prognosis and lack early effective screening markers. Wilm's tumor gene 1 ( WT1) is overexpressed in OCs. Therefore, it is of great interest to investigate whether WT1-specific antibody (Ab) measurements in plasma can serve as a biomarker of anti- OC response, and is of importance in relation to patient prognosis. Peripheral blood samples were obtained from a total of 103 women with ovarian tumors with median being 1 day (range 0-48 days) before operation. WT1 IgG Ab levels were evaluated using enzyme-linked immunosorbent assay ( ELISA). Immunohistochemical analysis of WT1 protein expression was performed on OC tissue samples. We found that low- WT1 Ab level in plasma was related to improved survival in patients diagnosed at stages III-IV and grade 3 carcinomas. Positive WT1 protein staining on OC tissue samples had a negative impact on survival in the entire cohort, both overall survival ( OS) ( P = 0.046) and progression-free survival ( PFS) ( P = 0.006), but not in the serous OC subtype. Combining WT1 IgG Ab levels and WT1 staining, patients with high- WT1 IgG Ab levels in plasma and positive WT1 protein staining in cancer tissues had shorter survival, with a significant association in PFS ( P = 0.016). These results indicated that WT1 Ab measurements in plasma and WT1 staining in tissue specimens could be useful as biomarkers for patient outcome in the high-risk subtypes of OCs for postoperative individualized therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
- Author
-
Alzaaqi, Shouq, Naka, Norifumi, Hamada, Kenichiro, Hosen, Naoki, Kanegae, Mizuki, Outani, Hidetatsu, Adachi, Mayuko, Imanishi, Rin, Morii, Eiichi, Iwai, Miki, Nakata, Jun, Fujiki, Fumihiro, Morimoto, Soyoko, Nakajima, Hiroko, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Sugiyama, Haruo, and Oji, Yusuke
- Subjects
- *
PEPTIDES , *CANCER vaccines , *ANTIGENS , *MONONUCLEAR leukocytes , *IMMUNOGLOBULIN G , *IMMUNOGLOBULINS - Abstract
The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL epitopes were developed as an immunotherapy for these malignancies. In the present study, WT1 epitope-specific immune responses were analyzed in 31 patients with advanced sarcoma with human leukocyte antigen-A*24:02- and WT1-expressing tumors who received the WT1-235 peptide vaccine as monotherapy. The serum levels of IgG and IgM antibodies against the target epitope WT1-235 and the non-target epitopes WT1-332 and WT1-271 were measured using ELISA. IgM antibodies against WT1-235, WT1-332 and WT1-271 were detected in three (9.6%), four (12.9%) and 20 patients (64.5%), respectively, prior to vaccine administration, indicating immune recognition of the WT1 antigen prior to administering the vaccine. Of 15 patients who had completed the 3-month treatment protocol, WT1-235 IgG was positive in five (33.3%) patients. An enzyme-linked immunospot assay revealed that WT1-235 epitope-specific IL-10 production/secretion in peripheral blood mononuclear cells declined in the first month of vaccine administration in all three patients with positivity for WT1-235 IgM at the start of the vaccine. Furthermore, positivity for both WT1-235 and WT1-271 IgM antibodies at the start of treatment was associated with unfavorable tumor control at 3 months after vaccine administration. These results suggested that WT1 epitope-specific IgG and IgM antibodies may be utilized as immune-monitoring markers for WT1 peptide cancer vaccine immunotherapy. The trials were entered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (https://www.umin.ac.jp/ctr ; no. UMIN000002001 on May 24, 2009 and no. UMIN000015997 on December 20, 2014). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Functional human Th17 clones with WT1-specific helper activity.
- Author
-
Tachino, Sho, Fujiki, Fumihiro, Oka, Yoshihiro, Tsuboi, Akihiro, Morimoto, Soyoko, Lin, Yu-Hung, Tamanaka, Taichi, Kondo, Kenta, Nakajima, Hiroko, Nishida, Sumiyuki, Hosen, Naoki, Oji, Yusuke, Kumanogoh, Atsushi, and Sugiyama, Haruo
- Subjects
- *
TUMORS , *AUTOIMMUNE diseases , *ANTIGENS , *CELLS , *INTERLEUKINS , *T cells - Abstract
Th17 plays important roles in the pathogenesis of various inflammatory and autoimmune diseases. Although the importance of Th17 in tumor immunity has also been suggested, precise roles of tumor-associated antigen-specific Th17 still remain poorly understood, especially in humans. We previously identified WT1, a 16-mer helper epitope derived from tumor-associated antigen Wilms' tumor gene 1 (WT1) product, and WT1-specific Th1 clones were established. In the present study, WT1-specific Th17 clones were established by the stimulation of peripheral blood mononuclear cells with the WT1 helper peptide under human Th17-polarizing conditions. The WT1-specific Th17 clone exhibited the helper function for proliferation of conventional CD4 T cells in the antigenic stimulation-specific manner. This is the first report of establishment of functional Th17 clones with both antigen (WT1) specificity and antigen-specific helper activity. Th17 clones established here and the method to establish antigen-specific Th17 clones should be a useful tool to further analyze the roles of human Th17 in tumor immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
- Author
-
Miyatake, Takashi, Ueda, Yutaka, Morimoto, Akiko, Enomoto, Takayuki, Nishida, Sumiyuki, Shirakata, Toshiaki, Oka, Yoshihiro, Tsuboi, Akihiro, Oji, Yusuke, Hosen, Naoki, Nakatsuka, Shin-ichi, Morita, Satoshi, Sakamoto, Junichi, Sugiyama, Haruo, and Kimura, Tadashi
- Subjects
- *
CANCER immunotherapy , *PEPTIDES , *CANCER vaccines , *ANTINEOPLASTIC agents , *CANCER in women , *CANCER invasiveness , *CLINICAL trials - Abstract
Objective: The aim of the present study was to analyze the long-term survival effects of WT1 peptide vaccine, in addition to its anti-tumor effects and toxicity. Methods: A phase II clinical trial was conducted during the period of 2004-2010 at Osaka University Hospital, Osaka, Japan. The patients who had gynecologic malignancies progressing against previous treatments received WT1 peptide vaccine intradermally at 1-week intervals for 12 weeks. The vaccination was allowed to further continue, unless the patient's condition became significantly worse due to the disease progression. Results: Forty out of 42 patients, who met all the inclusion criteria, underwent WT1 peptide vaccine. Among these 40 patients, stable disease was observed in 16 cases (40 %). Skin toxicity of a grade 1, 2 and 3 occurred in 25 cases (63 %), 9 cases (23 %) and a single case (3 %), respectively, and liver toxicity of grade 1 in a single case (3 %). The overall survival period was significantly longer in cases positive for the WT1 peptide-specific delayed-type hypersensitivity (DTH) reaction after the vaccination, compared to those negative for the DTH reaction ( p = 0.023). Multivariate Cox proportional hazards analysis demonstrated that the adjusted hazard ratio for the negative DTH reaction was 2.73 (95 % CI 1.04-7.19, p = 0.043). Conclusion: WT1 peptide vaccine may be a potential treatment, with limited toxicity, for gynecologic malignancies that have become resistant to conventional therapies. Larger scale of clinical studies is required to establish the efficacy of the WT1 peptide vaccine for gynecologic malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
28. Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study
- Author
-
Ogata, Kiyoyuki, Kakumoto, Keiji, Matsuda, Akira, Tohyama, Kaoru, Tamura, Hideto, Ueda, Yasunori, Kurokawa, Mineo, Takeuchi, Jin, Shibayama, Hirohiko, Emi, Nobuhiko, Motoji, Toshiko, Miyazaki, Yoshihide, Tamaki, Hiroya, Mitani, Kinuko, Naoe, Tomoki, Sugiyama, Haruo, and Takaku, Fumimaro
- Subjects
- *
MYELODYSPLASTIC syndromes treatment , *HUMAN phenotype , *FLOW cytometry , *GENE expression , *REGRESSION analysis , *DISEASE progression , *CD34 antigen - Abstract
Abstract: We conducted a multicenter, flow cytometry study to validate differences in immunophenotypes among disease types in melodysplastic syndromes (MDS). The data obtained from 115 patients were combined into three groups according to disease grade, i.e., low-grade MDS, refractory anemia with excess blasts, and acute leukemia transformed from MDS (AL-MDS). The data comparison showed that with the progression of disease grade, the immunophenotypes of CD34+ myeloblasts were more immature, with an increase and a decrease in CD7 and CD15 expression, respectively, and the percentages of CD34+ B-progenitors among total CD34+ cells and the granularity of granulocytes decreased. Logistic regression analyses showed that, in addition to myeloblast percentages, the expression of CD7 and B7-H1 on myeloblasts was independently associated with AL-MDS patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
29. Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.
- Author
-
Wada, Naoki, Zaki, Mona A A, Kohara, Masaharu, Ogawa, Hiroyasu, Sugiyama, Haruo, Nomura, Shosaku, Matsumura, Itaru, Hino, Masayuki, Kanakura, Yuzuru, Inagaki, Hiroshi, Morii, Eiichi, and Aozasa, Katsuyuki
- Subjects
- *
LYMPHOMAS , *MACROPHAGES , *PROGNOSIS , *IMMUNOGLOBULINS , *IN situ hybridization , *LACTATE dehydrogenase , *PEPTIDE nucleic acids - Abstract
Wada N, Zaki M A A, Kohara M, Ogawa H, Sugiyama H, Nomura S, Matsumura I, Hino M, Kanakura Y, Inagaki H, Morii E & Aozasa K (2012) Histopathology 60, 924-932 Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group Aims: ]Diffuse large B cell lymphoma (DLBCL) occasionally shows an interfollicular pattern of proliferation (DLBCL-IF) preserving lymphoid follicles. In this study, clinicopathological findings in 31 cases of DLBCL-IF were analysed. Methods and results: The study group comprised 20 males and 11 females, with ages ranging from 41 to 87 (median 69) years. The primary site was lymph node in 25 cases, and unknown in six due to advanced stage at diagnosis. Eight cases were clinical Stage I, 10 were Stage II, four Stage III, and nine Stage IV. A polymorphous pattern of proliferation containing large B cells and inflammatory cells was found in about 60% of cases. The overall survival rate of the DLBCL-IF patients was better than that of a DLBCL control group (log-rank test; P < 0.05). Multivariate analysis revealed that an interfollicular pattern of proliferation showed marginal significance for favourable prognosis ( P = 0.069). Immunohistochemical double staining with antibodies for HLA-DR/CD68 (markers for M1-tumour-associated macrophage [M1-TAM]) or CD163/CD68 (M2-TAM) revealed that all DLBCL-IF patients with a low M2 count were alive at the end of observation. Conclusions: These findings suggest that DLBCL-IF is a clinicopathological entity distinct from ordinary DLBCL. The possible origin of tumour cells in DLBCL-IF from marginal zone B cells is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
30. Low Wilms' Tumor Gene Expression in Tumor Tissues Predicts Poor Prognosis in Patients with Non-Small-Cell Lung Cancer.
- Author
-
Hayashi, Seiji, Oji, Yusuke, Kanai, Yuko, Teramoto, Tomoaki, Kitaichi, Masanori, Kawaguchi, Tomoya, Okada, Masaji, Sugiyama, Haruo, and Matsumura, Akihide
- Subjects
- *
NEPHROBLASTOMA , *GENE expression , *LUNG cancer prognosis , *TUMOR suppressor genes , *ONCOGENES , *TUMOR immunology , *LYMPH node cancer , *GENETICS - Abstract
We elucidated the relationship between prognosis of non-small-cell lung cancer (NSCLC) and Wilms' tumor gene ( WT1) mRNA expression in tumor tissue. The WT1 mRNA expression levels of the fatal cases were lower as compared with those of the survival cases. Overall survival (OS) and disease-free survival (DFS) of the high WT1 expression group were longer than of the low expression group. As for squamous cell lung cancer (SQLC), low WT1 expression was significantly associated with lymph node metastasis. Cox analysis revealed that the gene level was a significant prognostic factor in OS and DFS. Low WT1 expression predicted poor prognosis in patients with NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
31. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration
- Author
-
Nakajima, Hiroko, Oka, Yoshihiro, Tsuboi, Akihiro, Tatsumi, Naoya, Yamamoto, Yumiko, Fujiki, Fumihiro, Li, Zheyu, Murao, Ayako, Morimoto, Soyoko, Hosen, Naoki, Shirakata, Toshiaki, Nishida, Sumiyuki, Kawase, Ichiro, Isaka, Yoshitaka, Oji, Yusuke, and Sugiyama, Haruo
- Subjects
- *
TUMOR immunology , *PEPTIDES , *INTERFERONS , *CANCER immunology , *ANTIBODY-dependent cell cytotoxicity , *T cells , *MAJOR histocompatibility complex , *GENE expression - Abstract
Abstract: To induce and activate tumor-associated antigen-specific cytotoxic T lymphocytes (CTLs) for cancer immunity, it is important not only to select potent CTL epitopes but also to combine them with appropriate immunopotentiating agents. Here we investigated whether tumor immunity induced by WT1 peptide vaccination could be enhanced by IFN-β. For the experimental group, C57BL/6 mice were twice pre-treated with WT1 peptide vaccine, implanted with WT1-expressing C1498 cells, and treated four times with WT1 peptide vaccine at one-week intervals. During the vaccination period, IFN-β was injected three times a week. Mice in control groups were treated with WT1 peptide alone, IFN-β alone, or PBS alone. The mice in the experimental group rejected tumor cells and survived significantly longer than mice in the control groups. The overall survival on day 75 was 40% for the mice treated with WT1 peptide+IFN-β, while it was 7, 7, and 0% for those treated with WT1 peptide alone, IFN-β alone or PBS alone, respectively. Induction of WT1-specific CTLs and enhancement of NK activity were detected in splenocytes from mice in the experimental group. Furthermore, administration of IFN-β enhanced expression of MHC class I molecules on the implanted tumor cells. In conclusion, our results showed that co-administration of WT1 peptide+IFN-β enhanced tumor immunity mainly through the induction of WT1-specific CTLs, enhancement of NK activity, and promotion of MHC class I expression on the tumor cells. WT1 peptide vaccination combined with IFN-β administration can thus be expected to enhance the clinical efficacy of WT1 immunotherapy. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. CD48 as a novel molecular target for antibody therapy in multiple myeloma.
- Author
-
Hosen, Naoki, Ichihara, Hiroyoshi, Mugitani, Atsuko, Aoyama, Yasutaka, Fukuda, Yuki, Kishida, Satoshi, Matsuoka, Yoshikazu, Nakajima, Hiroko, Kawakami, Manabu, Yamagami, Tamotsu, Fuji, Shigeo, Tamaki, Hiroya, Nakao, Takafumi, Nishida, Sumiyuki, Tsuboi, Akihiro, Iida, Shinsuke, Hino, Masayuki, Oka, Yoshihiro, Oji, Yusuke, and Sugiyama, Haruo
- Subjects
- *
MULTIPLE myeloma , *PLASMACYTOMA , *MONOCLONAL gammopathies , *BONE marrow , *LEUCOCYTES , *KILLER cells , *MONOCLONAL antibodies - Abstract
Summary Monoclonal antibody (mAb) drugs are desirable for the improvement of multiple myeloma (MM) treatment. In this study, we found for the first time that CD48 was highly expressed on MM plasma cells. In 22 out of 24 MM patients, CD48 was expressed on more than 90% of MM plasma cells at significantly higher levels than it was on normal lymphocytes and monocytes. CD48 was only weakly expressed on some CD34+ haematopoietic stem/progenitor cells, and not expressed on erythrocytes or platelets. We next examined whether CD48 could serve as a target antigen for mAb therapy against MM. A newly generated in-house anti-CD48 mAb induced mild antibody-dependent cell-mediated cytotoxicity and marked complement-dependent cytotoxicity against not only MM cell lines but also primary MM plasma cells in vitro. Administration of the anti-CD48 mAb significantly inhibited tumour growth in severe combined immunodeficient mice inoculated subcutaneously with MM cells. Furthermore, anti-CD48 mAb treatment inhibited growth of MM cells transplanted directly into murine bone marrow. Finally and importantly, we demonstrated that the anti-CD48 mAb did not damage normal CD34+ haematopoietic stem/progenitor cells. These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
33. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
- Author
-
Takahara, Akitaka, Koido, Shigeo, Ito, Masaki, Nagasaki, Eijiro, Sagawa, Yukiko, Iwamoto, Takeo, Komita, Hideo, Ochi, Toshiki, Fujiwara, Hiroshi, Yasukawa, Masaki, Mineno, Junichi, Shiku, Hiroshi, Nishida, Sumiyuki, Sugiyama, Haruo, Tajiri, Hisao, and Homma, Sadamu
- Subjects
- *
ANTINEOPLASTIC agents , *NEPHROBLASTOMA , *GENE expression , *PANCREATIC cancer , *T cells , *IMMUNE response , *CANCER immunology , *NF-kappa B - Abstract
Wilms' tumor gene (WT1), which is expressed in human pancreatic cancer (PC), is a unique tumor antigen recognized by T-cell-mediated antitumor immune response. Gemcitabine (GEM), a standard therapeutic drug for PC, was examined for the regulation of WT1 expression and the sensitizing effect on PC cells with WT1-specific antitumor immune response. Expression of WT1 was examined by quantitative PCR, immunoblot analysis, and confocal microscopy. Antigenic peptide of WT1 presented on HLA class I molecules was detected by mass spectrometry. WT1-specific T-cell receptor gene-transduced human T cells were used as effecter T cells for the analysis of cytotoxic activity. GEM treatment of human MIAPaCa2 PC cells enhanced WT1 mRNA levels, and this increase is associated with nuclear factor kappa B activation. Tumor tissue from GEM-treated MIAPaCa2-bearing SCID mice also showed an increase in WT1 mRNA. Some human PC cell lines other than MIAPaCa2 showed up-regulation of WT1 mRNA levels following GEM treatment. GEM treatment shifted WT1 protein from the nucleus to the cytoplasm, which may promote proteasomal processing of WT1 protein and generation of antigenic peptide. In fact, presentation of HLA-A*2402-restricted antigenic peptide of WT1 (CMTWNQMNL) increased in GEM-treated MIAPaCa2 cells relative to untreated cells. WT1-specific cytotoxic T cells killed MIAPaCa2 cells treated with an optimal dose of GEM more efficiently than untreated MIAPaCa2 cells. GEM enhanced WT1 expression in human PC cells and sensitized PC cells with WT1-specific T-cell-mediated antitumor immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
34. Presence of B-cell clones in T-cell lymphoma.
- Author
-
Zaki, Mona A. A., Wada, Naoki, Kohara, Masaharu, Ikeda, Junichiro, Hori, Yumiko, Fujita, Shigeki, Ogawa, Hiroyasu, Sugiyama, Haruo, Hino, Masayuki, Kanakura, Yuzuru, Morii, Eiichi, and Aozasa, Katsuyuki
- Subjects
- *
B cells , *CLONING , *T-cell lymphoma , *EPSTEIN-Barr virus , *POLYMERASE chain reaction - Abstract
The presence of B-cell clones in 76 cases with peripheral T-cell lymphoma (PTCL) and precursor T-lymphoblastic lymphoma (T-LBL) and its correlation with Epstein-Barr virus (EBV) was studied. DNA was extracted from paraffin sections and/or fresh-frozen samples and then used for clonality analysis using a modified BIOMED-2 polymerase chain reaction (PCR)-based method. T- and B-cell clones were detected in 59 (77.6%) and 14 (18.4%) of 76 patients, respectively: 90% and 30% of cases with PTCL, not otherwise specified, 76.4% and 17.6% of cases with angioimmunoblastic T-cell lymphoma, 77% and 7.6% of cases with adult T-cell lymphoma, 50% and 0% of cases with anaplastic large T-cell lymphoma, 62.5% and 12.5% of cases with T-LBL, and 50% and 0% of cases with intestinal T-cell lymphoma, respectively. Histological and immunohistochemical analyses revealed the presence of large B cells in lesional tissues, which were occasionally monoclonal. The presence of B-cell clones was highly associated with EBV positivity, as revealed by in situ hybridization. In two cases that were evaluated by serial histological and molecular examination, EBV-positive cells persisted in one and disappeared in the other. These findings suggest a role for EBV in the evolution of B-cell clones in T-cell lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
35. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes
- Author
-
Tamura, Hideto, Dan, Kazuo, Yokose, Norio, Iwakiri, Rika, Ohta, Masatsugu, Sakamaki, Hisashi, Tohyama, Kaoru, Kondo, Asaka, Hyodo, Hideya, Nakamura, Kyoko, Yamashita, Taishi, Elisseeva, Olga A., Oka, Yoshihiro, Oji, Yusuke, Sugiyama, Haruo, and Ogata, Kiyoyuki
- Subjects
- *
MYELODYSPLASTIC syndromes , *MESSENGER RNA , *IMMUNOGLOBULINS , *BLOOD cells , *NEPHROBLASTOMA , *GENE expression , *ACUTE myeloid leukemia , *FOLLOW-up studies (Medicine) , *PROGNOSIS - Abstract
Abstract: Wilms tumor gene (WT1) mRNA expression in peripheral blood cells was examined in 80 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) transformed from MDS. Serum anti-WT1 antibody titers were also determined in 45 patients. Their long-term follow-up showed that the survival rate became worse as the WT1 mRNA level increased. In particular, a high WT1 mRNA level was a strong predictor of a short time to AML transformation even if adjusted by the International Prognostic Scoring System category. Moreover, high values of anti-WT1 antibody were an independent predictor of longer survival. These data may justify therapeutic strategies targeting WT1 molecules in MDS. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
36. Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group
- Author
-
Wada, Naoki, Kohara, Masaharu, Ikeda, Junichiro, Hori, Yumiko, Fujita, Shigeki, Okada, Masaya, Ogawa, Hiroyasu, Sugiyama, Haruo, Fukuhara, Shirou, Kanamaru, Akihisa, Hino, Masayuki, Kanakura, Yuzuru, Morii, Eiichi, and Aozasa, Katsuyuki
- Subjects
- *
B cells , *EPIDURAL anesthesia , *LYMPHOMAS , *EPSTEIN-Barr virus , *IMMUNOHISTOCHEMISTRY , *CENTRAL nervous system - Abstract
Abstract: Diffuse large B-cell lymphoma (DLBCL) involving spinal epidural space (SEDLBCL) is relatively rare, constituting 1.8% of DLBCLs in Osaka, Japan. The aim of this study was to analyze SEDLBCL cases for their clinical and histopathologic findings, including an association with Epstein-Barr virus (EBV) and immunohistochemical characteristics. We analyzed the clinicopathologic findings of 27 SEDLBCL cases. They consisted of 16 males and 11 females, their age ranging from 37–86 years (median 64 years). Eight patients had stage I disease, 3 had stage II, 5 had stage III, and 11 had stage IV. Based on the staining pattern for anti-CD10, bcl-6, and MUM-1, the cases were categorized into 17 cases of the germinal center B-cell (GCB) type and nine of the non-GCB type. There was a 4%-positive rate for EBV in the tumor cells. When compared to nodal DLBCL, the frequency of patients with a high performance status (PS) is higher in SEDLBCL. Compared to the DLBCL of the central nervous system (CNS), the frequency of cases with high stage, 2 or more extranodal lesions, high international prognostic index (IPI), and GCB-type is higher in SEDLBCL. There were no significant differences in the histologic features between SEDLBCL and nodal/CNS DLBCL. Univariate analysis revealed that advanced stage was an unfavorable factor for overall survival (P=0.060). SEDLBCL is different from nodal and CNS DLBCL, but an association with EBV is unlikely in every group. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
37. WT1 (WILMS TUMOR 1) PEPTIDE IMMUNOTHERAPY FOR CHILDHOOD RHABDOMYOSARCOMA: A Case Report.
- Author
-
Ohta, Hideaki, Hashii, Yoshiko, Yoneda, Akihiro, Takizawa, Sachiko, Kusuki, Shigenori, Tokimasa, Sadao, Fukuzawa, Masahiro, Tsuboi, Akihiro, Murao, Ayako, Oka, Yoshihiro, Oji, Yusuke, Aozasa, Katsuyuki, Nakatsuka, Shin-ichi, Sugiyama, Haruo, and Ozono, Keiichi
- Subjects
- *
IMMUNOTHERAPY , *NEPHROBLASTOMA , *LEUKEMIA , *RHABDOMYOSARCOMA , *CLINICAL trials , *CANCER patients - Abstract
Immunotherapy using a Wilms tumor (WT1) peptide has been undergoing clinical trials for adulthood leukemia and solid cancer with promising results. In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma. She received weekly intradermal injection with HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs). A high proportion of WT1-specific CTLs with effector or effector memory phenotype were detected in peripheral blood of this patient. She is currently still on continued WT1 peptide immunotherapy in a disease-free condition for 22 months. WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
38. Differential radiation sensitivity to morphological, functional and molecular changes of human thyroid tissues and bone marrow cells maintained in SCID mice
- Author
-
Nomura, Taisei, Hongyo, Tadashi, Nakajima, Hiroo, Li, Li Ya, Syaifudin, Mukh, Adachi, Shigeki, Ryo, Haruko, Baskar, Rajamanickam, Fukuda, Kazuyasu, Oka, Yoshihiro, Sugiyama, Haruo, and Matsuzuka, Fumio
- Subjects
- *
SEVERE combined immunodeficiency , *LABORATORY mice , *GENETIC polymorphisms , *GENETIC mutation , *GENE expression , *PHYSIOLOGICAL effects of radiation , *THYROID gland , *BONE marrow cells - Abstract
Abstract: Morphology and function of human organs and tissues are well maintained in the improved SCID (severe combined immunodeficient) mice for a long period (∼3 years). To study the radiation-induced damage on human thyroid gland, human thyroid tissues transplanted to SCID mice were consecutively exposed to X-rays or 137Cs γ-rays at high and low dose rates for approximately 2 years. Consecutive irradiation resulted in the disappearance of follicles and significant decrease of thyroid hormone secretion. Mutations in p53 and c-kit genes were induced significantly in human thyroid tissues from old head and neck cancer patients (av. 56.8 years, 4 males) and a Graves’ disease patient (20 years, male) over the dose of 24Gy (44.7±5.9Gy, mean±S.E) and 11Gy (20.2±7.8Gy), respectively, while mutations were not detected at lower doses nor in unexposed matched controls (p <0.01). There were significant differences in mutation frequency in the transplanted human thyroid tissues (31 years, female) between high dose rate (1.19Gy/min; 8 in 20 tissues) and low dose rate (0.00023Gy/min; 0 in 14 tissues) exposures (p <0.01). Mutations were not detected in RET, K-ras and β-catenin genes. Expression analysis by GeneChip indicated that gene expression was also well maintained in the transplanted human thyroid tissues. However, lower doses (1 or 3Gy) of 137Cs γ-rays can induce changes in gene expression in the transplanted human thyroid tissues. Furthermore, fatally irradiated SCID mice could survive with human bone marrow cell transplantation. When about half of mouse bone marrows were replaced by human bone marrow cells, the human bone marrow cells showed high sensitivity to γ-irradiation; 28.0% and 0.45% survival after 0.5 and 2.0Gy exposures, respectively. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
39. WT1 peptide vaccine for the treatment of cancer
- Author
-
Oka, Yoshihiro, Tsuboi, Akihiro, Oji, Yusuke, Kawase, Ichiro, and Sugiyama, Haruo
- Subjects
- *
PEPTIDES , *VACCINES , *CANCER treatment , *T cells - Abstract
Wilms’ tumor gene WT1 is expressed in various kinds of cancers. Human WT1-specific cytotoxic T lymphocytes (CTLs) were generated, and mice immunized with WT1 peptide rejected challenges by WT1-expressing cancer cells without auto-aggression to normal organs. Furthermore, WT1 antibodies and WT1-specific CTLs were detected in cancer patients, indicating that WT1 protein was immunogenic. These findings provided us with the rationale for cancer immunotherapy targeting WT1. Clinical trials of WT1 peptide vaccination for cancer patients were started, and WT1 vaccination-related immunological responses and clinical responses, including reduction of leukemic cells, reduction of M-protein amount in myeloma, and shrinkage of solid cancer, were observed. Valuable information about immune responses against tumor antigens can be obtained by the analysis of samples from the vaccinated patients, which should lead to further improvement of cancer vaccine. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
40. The expression of anamorsin in diffuse large B cell lymphoma: Possible prognostic biomarker for low IPI patients.
- Author
-
Shizusawa, Takae, Shibayama, Hirohiko, Murata, Shinsuke, Saitoh, Yuri, Sugimoto, Yuna, Matsumura, Itaru, Ogawa, Hiroyasu, Sugiyama, Haruo, Fukuhara, Shirou, Hino, Masayuki, Kanamaru, Akihisa, Yamauchi, Amane, Aozasa, Katsuyuki, and Kanakura, Yuzuru
- Subjects
- *
GENE expression , *B cells , *LYMPHOMAS , *PROGNOSIS , *BIOMARKERS , *RANDOMIZED controlled trials - Abstract
Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies. About 40% (89/234) of sections from patients with diffuse large B cell lymphoma (DLBCL) showed strong anamorsin expression. Comparing the level of anamorsin expression in DLBCL patients with their clinical features (i.e., overall survival rate, International Prognostic Index (IPI) parameters, and treatment response) revealed no significant correlation between anamorsin expression levels and these clinical features. However, anamorsin expression in DLBCL patients with a low IPI was shown to be an unfavorable biomarker, especially in the patients who received chemotherapy without rituximab. It is suggested that anamorsin might play some roles in the abnormal growth of DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
41. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
- Author
-
Nakamichi, Itsuko, Tomita, Yasuhiko, Zhang, Binglin, Sugiyama, Haruo, Kanakura, Yuzuru, Fukuhara, Shirou, Hino, Masayuki, Kanamaru, Akihisa, Ogawa, Hiroyasu, and Aozasa, Katsuyuki
- Subjects
- *
LYMPHOMAS , *B cell lymphoma , *DRUG therapy , *GLUTATHIONE transferase , *METHYLTRANSFERASES , *MESSENGER RNA - Abstract
Glutathione-S-transferase P1 (GSTP1) and O6-methylguanine DNA methyltransferase (MGMT) are involved in drug-resistant to chemotherapeutic agents such as doxorubicin. In this study, prognostic significance of promoter hypermethylation and mRNA and protein expression of GSTP1 and MGMT together with promoter hypermethylation of death-associated protein kinase ( DAPK) in diffuse large B cell lymphoma (DLBCL) was analyzed. Fifty-three patients with DLBCL, 24 men and 29 women, with age ranging from 23 to 91 (median 65), were analyzed. Genomic DNA and total RNA extracted from frozen samples of DLBCL were analyzed by methylation-specific polymerase chain reaction and quantitative reverse transcription polymerase chain reaction (RT-PCR) to determine promoter hypermethylation and mRNA expression of GSTP1, MGMT, and DAPK. Immunohistochemical analysis was performed to determine GSTP1 and MGMT expression at the protein level. Promoter hypermethylation of GSTP1, MGMT, and DAPK was detected in 12 (22.6%), 21 (39.6%), and 36 (67.9%) of 53 patients, respectively. Quantitative RT-PCR and immunohistochemistry did not show a correlation between methylation status and mRNA and protein expression of GSTP1 and MGMT. Patients with GSTP1 promoter hypermethylation showed a better 5-year overall survival rate than those without (100 vs 62.2%; p < 0.05). However, GSTP1 promoter hypermethylation was not an independent prognosticator in multivariate analysis. Methylation status of GSTP1 could be an indicator of drug response and a prognosticator for DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
42. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
- Author
-
Hosen, Naoki, Park, Christopher V., Tatsumi, Naoya, Oji, Yusuke, Sugiyama, Haruo, Gramatzki, Martin, Krensky, Alan M., and Weissman, Irving L.
- Subjects
- *
ACUTE myeloid leukemia , *HEMATOPOIETIC stem cells , *STEM cells , *CANCER chemotherapy , *LEUKEMIA , *CELL surface antigens , *PREVENTIVE medicine , *LABORATORY mice - Abstract
Permanent cure of acute myeloid leukemia (AML) by chemotherapy alone remains elusive for most patients because of the inability to effectively eradicate leukemic stem cells (LSCs), the self-renewing component of the leukemia. To develop therapies that effectively target LSC. one potential strategy is to identify cell surface markers that can distinguish LSC from normal hematopoietic stem cells (HSCs). In this study, we employ a signal sequence trap strategy to isolate cell surface molecules expressed on human AML-LSC and find that CD96, which is a member of the Ig gene superfamily, is a promising candidate as an LSC-specific antigen. FACS analysis demonstrates that CD96 is expressed on the majority of CD34+CD38- AML cells in many cases (74.0 ± 25.3% in 19 of 29 cases), whereas only a few (4.9 ± 1.6%) cells in the normal HSC-enriched population (LinCD34-CD38+CD90+) expressed CD96 weakly. To examine whether CD96+ AML cells are enriched for LSC activity, we separated AML cells into CD96+ and CD96+ fractions and transplanted them into irradiated newborn Rag2-/- γ,c-/- mice. In four of five samples, only CD96+ cells showed significant levels of engraftment in bone marrow of the recipient mice. These results demonstrate that CD96 is a cell surface marker present on many AML-LSC and may serve as an LSC-specific therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
43. Intravenous administration of MIP-1α with intra-tumor injection of P. acnes shows potent anti-tumor effect
- Author
-
Nakano, Akiko, Yoneyama, Hiroyuki, Ueha, Satoshi, Kitabatake, Masahiro, Ishikawa, Sho, Kawase, Ichiro, Sugiyama, Haruo, and Matsushima, Kouji
- Subjects
- *
DENDRITIC cells , *INTRAVENOUS therapy , *IMMUNOLOGICAL adjuvants , *ANTINEOPLASTIC agents , *VACCINATION , *CUTIBACTERIUM acnes - Abstract
Abstract: Dendritic cells (DCs) play a key role as potent biological adjuvants in anti-tumor host responses. However, DC-based vaccination does not always eradicate tumors effectively. Clinical evidence suggests that a strategy to recruit a substantial number of DCs into the tumor mass might provoke proficient anti-tumor immune responses. Here we describe that myeloid DCs (mDCs) efficiently accumulate in tumor sites after intravenous injection of recombinant macrophage inflammatory protein (MIP)-1α when pretreated locally with adjuvants like Propionibacterium acnes. Combined treatment of tumor-bearing mice with MIP-1α and P. acnes also recruited a large number of natural killer cells (NK cells) to both tumor sites and regional lymph nodes (LNs) and induced a strong T helper 1 immunity at an early time. This early response later led to accumulation of CD8+ T cells, retraction of tumors and survival of animals treated with P. acnes/MIP-1α. In vivo depletion of NK cells or CD8+ T cells impaired anti-tumor effects, suggesting that activation of NK cells and CD8+ T cells contributes to anti-tumor immunity in this model. Therefore, this study provides a novel therapeutic strategy for cancer treatment using MIP-1α and certain adjuvants. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
44. The Wilms’ tumor gene WT1 is a common marker of progenitor cells in fetal liver
- Author
-
Kanato, Keisuke, Hosen, Naoki, Yanagihara, Masashi, Nakagata, Naomi, Shirakata, Toshiaki, Nakazawa, Tsutomu, Nishida, Sumiyuki, Tsuboi, Akihiro, Kawakami, Manabu, Masuda, Tomoki, Oka, Yoshihiro, Oji, Yusuke, IJpenberg, Annemieke, Hastie, Nicholas D., and Sugiyama, Haruo
- Subjects
- *
FETAL liver cells , *CELL proliferation , *GENES , *HEPATOCYTE growth factor - Abstract
Abstract: It is well known that the Wilms’ tumor gene WT1 plays an important role in cell proliferation and differentiation, and in organ development. In this study, to examine the role of the WT1 gene in lineage determination, fetal liver cells from LacZ-transgenic mice, in which WT1 expression was marked by the expression of the LacZ gene driven by WT1 promoter, were FACS-sorted according to LacZ expression of high (LacZ++) or undetectable (LacZ−) levels, which paralleled endogenous WT1 expression levels. LacZ++ fetal liver cells were enriched by hepatocyte and endothelial progenitor cells. These results indicated that WT1 expression is a common marker of both hepatocyte and endothelial progenitors. These results also implied a role of the WT1 gene in lineage determination. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
45. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
- Author
-
Nakajima, Hiroko, Kawasaki, Kotomi, Oka, Yoshihiro, Tsuboi, Akihiro, Kawakami, Manabu, Ikegame, Kazuhiro, Hoshida, Yoshihiko, Fujiki, Fumihiro, Nakano, Akiko, Masuda, Tomoki, Wu, Fei, Taniguchi, Yuki, Yoshihara, Satoshi, Elisseeva, Olga A., Oji, Yusuke, Ogawa, Hiroyasu, Azuma, Ichiro, Kawase, Ichiro, Aozasa, Katsuyuki, and Sugiyama, Haruo
- Subjects
- *
BREAST cancer , *LEUKEMIA , *PEPTIDE drugs , *VACCINATION , *TUMORS , *IMMUNOTHERAPY - Abstract
A Wilms’ tumor gene WT1 is expressed at high levels not only in most types of leukemia but also in various types of solid tumors, including lung and breast cancer. WT1 protein has been reported to serve as a target antigen for tumor-specific immunotherapy both in vitro in human systems and in vivo in murine models. We have shown that mice immunized with WT1 peptide or WT1 cDNA could reject a challenge from WT1-expressing tumor cells (a “prophylactic” model). However, it was not examined whether WT1 peptide vaccination had the potency to reject tumor cells in a “therapeutic” setting. In the present study, we demonstrated for the first time that WT1 peptide vaccination combined with Mycobacterium bovis bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) was more effective for eradication of WT1-expressing tumor cells that had been implanted into mice before vaccination (a “therapeutic” model) compared with WT1 peptide vaccination alone. An intradermal injection of BCG-CWS into mice, followed by that of WT1 peptide at the same site on the next day, generated WT1-specific cytotoxic T lymphocytes (CTLs) and led to rejection of WT1-expressing leukemia or lung cancer cells. These results showed that BCG-CWS, which was well known to enhance innate immunity, could enhance WT1-specific immune responses (acquired immunity) in combination with WT1 peptide vaccination. Therefore, WT1 peptide vaccination combined with BCG-CWS may be applied to cancer immunotherapy in clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
46. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
- Author
-
Fujioka, Tatsuya, Taniguchi, Yuki, Masuda, Tomoki, Nishida, Sumiyuki, Ikegame, Kazuhiro, Kawakami, Manabu, Tsuboi, Akihiro, Hosen, Naoki, Murakami, Masaki, Oji, Yusuke, Oka, Yoshihiro, Sugiyama, Haruo, Kawase, Ichiro, and Ogawa, Hiroyasu
- Subjects
- *
CELL transplantation , *MAJOR histocompatibility complex , *T cells , *CELL proliferation , *APOPTOSIS - Abstract
Activation-induced cell death (AICD) of lymphocytes is an apoptotic pathway involved in the control of T-cell homeostasis. The magnitude of graft-vs.-host disease (GVHD) following allogeneic hematopoietic cell transplantation may be attenuated by the enhancement of AICD. The aim of the present study was to clarify the effect of T cell dose upon the fate (proliferation or apoptosis) of individual activated T cells in a murine GVHD model. To this end, we investigated the kinetics of the proliferation and apoptosis of donor T cells in recipient spleens in the early stage of a fully major histocompatibility complex (MHC)mismatched murine transplantation model from C57BL/6 (H-2[sup b]) to lethally-irradiated (8.5 Gy) BALB/c (H-2[sup d]) mice. To track the behavior of alloreactive lymphocytes in vivo, we used the fluorescent cytoplasmic dye carboxyfluorescein diacetate succinimidyl ester in combination with flow cytometry. Engraftment of donor T cells to recipient spleens was almost completed within 24 h after transfer. After that, at higher doses of transferred cells, the donor T cells actively divided for up to 72 h resulting in a 30fold increase in cell number at the maximum cell dose (2.0 × 10[sup 7]). As the transferred cell dose decreased, the proliferation of T cells tended to be suppressed. At cell doses of 0.5 × 10[sup 7] or less, the proliferation of T cells was profoundly suppressed, ultimately resulting in little proliferation of donor T cells observed from 24 to 72 h at the minimum cell dose (0.1 × 10[sup 7]). The frequency of Annexin-V-positive cells was found to increase gradually as the transferred cell dose decreased. Thus, an increase in apoptotic events appeared to play an important role in the suppression of the proliferation of T cells at lower splenocyte doses. Further analyses revealed that Fas ligand (FasL)-positive T cells were observed exclusively among T cells that divided at least 5 times, and that all of them were... [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
47. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
- Author
-
Hosen, Naoki, Sonoda, Yoshiaki, Oji, Yusuke, Kimura, Takafumi, Minamiguchi, Hitoshi, Tamaki, Hiroya, Kawakami, Manabu, Asada, Momotaro, Kanato, Keisuke, Motomura, Mari, Murakami, Masaki, Fujioka, Tatsuya, Masuda, Tomoki, Kim, Eui Ho, Tsuboi, Akihiro, Oka, Yoshihiro, Soma, Toshihiro, Ogawa, Hiroyasu, and Sugiyama, Haruo
- Subjects
- *
NEPHROBLASTOMA , *BLOOD cells ,LEUKEMIA genetics - Abstract
Summary. The Wilms' tumour gene, WT1, is expressed at high levels in leukaemia cells and plays an important role in leukaemogenesis. WT1 is also expressed in human normal CD34+ bone marrow (BM) cells at about 100 times lower levels than in leukaemia cells. To identify and characterize WT1-expressing cells in CD34+ BM cells, they were sorted into single cells and analysed for WT1 expression using two kinds of single-cell reverse transcriptase polymerase chain reaction (RT–PCR) methods. Using the semiquantitative single-cell polyA-PCR + sequence-specific (SS)-PCR method, WT1 expression was detected in four (1·3%) out of 319 CD34+ BM single cells. To confirm the above results, a single-cell nested sequence-specific (NSS)-RT–PCR method that was less quantitative but more sensitive than the polyA-PCR + SS-PCR method was also performed, and WT1 expression was detected in 15 (1·1%) out of 1315 CD34+ BM single cells. In total, WT1 expression was found in 19 (1·2%) out of 1634 CD34+ BM single cells. No significant differences in the frequencies of WT1-expressing cells were found between CD34+ CD38– and CD34+ CD38+ BM single cells. Furthermore, WT1-expressing CD34+ BM single cells expressed WT1 at levels similar to those in K562 leukaemia single cells. Analysis of lineage-specific and cell cycle gene expression in WT1-expressing CD34+ BM single cells showed that the WT1 gene could be expressed in both uncommitted, dormant CD34+ CD38– and lineage-committed, proliferating CD34+ CD38+ BM cells. Our results could indicate that these WT1-expressing CD34+ BM cells were normal counterparts of leukaemia cells. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
48. Imaging Assessment of Tumor Response in the Era of Immunotherapy.
- Author
-
Nakata, Jun, Isohashi, Kayako, Oka, Yoshihiro, Nakajima, Hiroko, Morimoto, Soyoko, Fujiki, Fumihiro, Oji, Yusuke, Tsuboi, Akihiro, Kumanogoh, Atsushi, Hashimoto, Naoya, Hatazawa, Jun, and Sugiyama, Haruo
- Subjects
- *
MAGNETIC resonance imaging , *COMPUTED tomography , *POSITRON emission tomography , *IMMUNOTHERAPY , *DISEASE progression - Abstract
Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid tumors (PERCIST) were, respectively, the established morphologic and metabolic response criteria, and cessation of treatment was recommended when progressive disease was detected according to these criteria. However, various types of immunotherapy have been developed over the past 20 years, which show novel false positive findings on images, as well as distinct response patterns from conventional therapies. Antitumor immune response itself causes 18F-fluorodeoxyglucose (FDG) uptake in tumor sites, known as "flare phenomenon", so that positron emission tomography using FDG can no longer accurately identify remaining tumors. Furthermore, tumors often initially increase, followed by stability or decrease resulting from immunotherapy, which is called "pseudoprogression", so that progressive disease cannot be confirmed by computed tomography or magnetic resonance imaging at a single time point. As a result, neither RECIST nor PERCIST can accurately predict the response to immunotherapy, and therefore several new response criteria fixed for immunotherapy have been proposed. However, these criteria are still controversial, and also require months for response confirmation. The establishment of optimal response criteria and the development of new imaging technologies other than FDG are therefore urgently needed. In this review, we summarize the false positive images and the revision of response criteria for each immunotherapy, in order to avoid discontinuation of a truly effective immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Frequency of intravascular large B-cell lymphoma in Japan: Study of the Osaka Lymphoma Study Group.
- Author
-
Chihara, Takeshi, Wada, Naoki, Ikeda, Junichiro, Fujita, Shigeki, Hori, Yumiko, Ogawa, Hiroyasu, Sugiyama, Haruo, Nomura, Shosaku, Matsumura, Itaru, Hino, Masayuki, Kanakura, Yuzuru, Morii, Eiichi, and Aozasa, Katsuyuki
- Subjects
- *
LETTERS to the editor , *LYMPHOMAS - Abstract
A letter to the editor is presented in response to an article on the frequency of intravascular large B-cell lymphoma in Japan that was published in a previous issue.
- Published
- 2011
- Full Text
- View/download PDF
50. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
- Author
-
Oji, Yusuke, Oka, Yoshihiro, Nishida, Sumiyuki, Tsuboi, Akihiro, Kawakami, Manabu, Shirakata, Toshiaki, Takahashi, Kazuko, Murao, Ayako, Nakajima, Hiroko, Narita, Miwako, Takahashi, Masuhiro, Morita, Satoshi, Sakamoto, Junichi, Tanaka, Toshio, Kawase, Ichiro, Hosen, Naoki, and Sugiyama, Haruo
- Subjects
- *
CASE studies , *IMATINIB , *CHRONIC myeloid leukemia , *VACCINES , *IMMUNE response , *PATIENTS - Abstract
How to treat CML patients who are resistant to inhibitors of BCR-ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib-treated CML in which intradermally administered WT1 peptide vaccine elicited WT1-specific immune responses and the resultant reduction in the persistent residual disease in co-administration of Imatinib. BCR-ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR-ABL mRNA levels was associated with the increase in frequency of WT1-specific cytotoxic T lymphocytes, notably effector-memory type of that, in the patient's peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure-oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.